Imprivata
Device Security PlatformsHTMwire assessment
Healthcare digital identity platform — SSO, MFA, proximity badge authentication, privileged access, and medical device access controls for HIPAA.
Key Features
- ✓ Single Sign-On (SSO) and Multifactor Authentication (MFA) for clinical workstations
- ✓ Proximity badge tap-in/tap-out authentication with auto-lock
- ✓ Privileged Access Management (PAM) for admin and vendor accounts
- ✓ Medical device access management with audit trails
- ✓ Patient privacy monitoring and drug diversion detection
What It Helps You Do
What Sets Them Apart
Healthcare-focused digital identity platform with proximity badge SSO, privileged access management, and medical device access controls — reducing clinician login time while enforcing HIPAA compliance.
How Imprivata Uses AI
HTMwire's independent read on the technology — not the vendor's marketing claim.
- Patient privacy analytics. Imprivata FairWarning applies machine learning to detect anomalous access to protected health information across many data sources.
- Drug diversion detection. ML-driven analytics flag patterns indicative of drug diversion and insider threats in healthcare systems.
Key Numbers
- ▪ Acquired by Thoma Bravo (2016) for ~$544M
- ▪ More than 6M users across 1,900+ healthcare organizations in 45 countries
Tags
Trust Signals
Frequently Asked Questions
What is Imprivata's core product for hospitals?
Imprivata OneSign is its flagship single sign-on (SSO) product, widely paired with proximity badge tap-in/tap-out authentication so clinicians can quickly access shared workstations and applications while enforcing HIPAA-aligned access controls.
Who owns Imprivata?
Imprivata is owned by private equity firm Thoma Bravo, which acquired it in September 2016 in an all-cash transaction valued at approximately $544 million.
Does Imprivata use AI or machine learning anywhere?
Yes, through FairWarning, which Imprivata acquired in December 2020. The FairWarning platform applies machine learning and AI to patient-privacy intelligence and drug-diversion analytics, detecting anomalous access to protected health information.
How widely is Imprivata used in healthcare?
Imprivata is a healthcare digital identity leader; a corporate brochure cited more than 6 million users across over 1,900 healthcare organizations in 45 countries. Named customers include Penn State Health, Seattle Children's Hospital, and Atrium Health.
Sources
- Imprivata agrees to be acquired by Thoma Bravo (~$544M)
- Imprivata acquires FairWarning (ML patient privacy, drug diversion)
- Imprivata corporate brochure: 6M+ users, 1,900+ organizations, 45 countries
We cite a primary or named source for every claim on this page. How we evaluate →